Grifols, S.A. (NASDAQ:GRFS) to Issue $0.09 Special Dividend

Grifols, S.A. (NASDAQ:GRFS) announced a special dividend on Monday, June 22nd. Investors of record on Thursday, July 2nd will be given a dividend of 0.0945 per share by the biotechnology company on Thursday, July 9th. The ex-dividend date of this dividend is Thursday, July 2nd.

Grifols has a dividend payout ratio of 12.7% indicating that its dividend is sufficiently covered by earnings. Analysts expect Grifols to earn $1.34 per share next year, which means the company should continue to be able to cover its $0.14 annual dividend with an expected future payout ratio of 10.4%.

Grifols Stock Performance

GRFS traded down $0.10 on Tuesday, hitting $7.18. 438,013 shares of the stock traded hands, compared to its average volume of 653,249. Grifols has a 52 week low of $7.16 and a 52 week high of $11.14. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. The firm has a market capitalization of $4.89 billion, a PE ratio of 37.82, a P/E/G ratio of 0.29 and a beta of 0.65. The business has a fifty day moving average price of $7.92 and a two-hundred day moving average price of $8.51.

Grifols (NASDAQ:GRFS) last announced its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. Grifols had a return on equity of 6.21% and a net margin of 5.54%.The company had revenue of $2.32 billion during the quarter. On average, research analysts predict that Grifols will post 1.06 EPS for the current fiscal year.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.